 |
Onglyza reduces blood sugar levels: studyPharmaceutical companies Bristol-Myers Squibb and AstraZeneca have announced results from an investigational phase 3b clinical study of use of Onglyza (saxagliptin) in diabetic patients. The study was based on the addition of Onglyza (saxa More… |
Thursday 18 April 2024
